Clinical trial
Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib
NCT00352859 · Bayer, Industry · Terminated
Key facts
| NCT number | NCT00352859 |
|---|---|
| Title | Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib |
| Official title | A Randomized Discontinuation Trial to Determine the Clinical Benefit of Continuation of Sorafenib Following Disease Progression in Patients With Advanced Renal Cell Carcinoma |
| Lead sponsor | Bayer, Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Drug |
| Interventions | Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon, Gemcitabine or Interferon (only) |
| Enrollment | 2 |
| Start date | Aug 1, 2006 |
| Completion | Nov 1, 2006 |
| First posted | Jul 17, 2006 |
| Last update posted | Dec 30, 2014 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: